Journal of cancer research and therapeutics · 2024
Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report.
СтатьяКлинические рекомендацииConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Bin, Huang Wei, Zhang Fujun, Wang Junjie, Guo Jinhe, Huang Xuequan, Lei Guangyan, Wang Juan, Ye Xin, Wang Ruoyu, Gai Baodong, Hu Xiaokun, Li Maoquan, Li Chengli, Xiao Yueyong, Lin Zhengyu, Niu Lizhi, Zhu Guangyu, Gao Fei, Niu Hongxin, Zhang Hongtao, Wu Qing, Yang Jijin, Zhao Hong, Zhang Kaixian, Chen Zhijin, Chen Tingsong, Zhang Haoren, Wang Zhongmin, Li Yuliang
Аннотация
The incidence of pancreatic cancer is increasing worldwide. Approximately, 60% of patients with pancreatic cancer have distant metastases at the time of diagnosis, of which only 10% can be removed using standard resection. Further, patients derive limited benefits from chemotherapy or radiotherapy. As such, alternative methods to achieve local control have emerged, including permanent iodine-125 seed interstitial brachytherapy. In 2023, the Chinese College of Interventionalists, affiliated with the Chinese Medical Doctor Association, organized a group of multi-disciplinary experts to compose guidelines for this treatment modality. The aim of this conference was to standardize the procedure for permanent iodine-125 seed interstitial brachytherapy, including indications, contraindications, pre-procedural preparation, procedural operations, complications, efficacy evaluation, and follow-up.